Contribute Try STAT+ Today

Even as hopes soar that soon-to-be-distributed Covid-19 vaccines will help quench the global coronavirus pandemic, there are still concerns about the rapid speed with which these vaccines were developed. And with some estimates suggesting that the global Covid-19 vaccine market could surpass $40 billion in 2021 alone, this scrutiny is likely to continue.

It is a tension replicated across a range of other activities in the sector. As Liz Szabo wrote last year in Scientific American, “Many doctors and consumer advocates fear that the tech industry, which lives by the mantra ‘fail fast and fix it later,’ is putting patients at risk — and that regulators aren’t doing enough to keep consumers safe.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.